**Bisguanidine, Bis(2-aminoimidazoline) and Polyamine Derivatives as
Potent and Selective Chemotherapeutic Agents against *Trypanosoma
brucei rhodesiense*. Synthesis and *in vitro* evaluation.**

Christophe Dardonville^{a*} and Reto Brun^b

^a*Instituto de Química Médica, CSIC, Juan de la Cierva, 3, 28006-Madrid, Spain*

^b*Swiss Tropical Institute, Socinstrasse 57, CH-4002 Basel, Switzerland*

* Corresponding author

Instituto de Química Médica, CSIC

Juan de la Cierva, 3, 28006-Madrid, Spain

Tel.: +34 91-562-2900

Fax.: +34 91-564-4853

E-mail : dardonville@iqm.csic.es

TOC Graphic

Abstract

The *in vitro* screening for trypanocidal activity against *T.b. rhodesiense* of an in-house library of 62 compounds [i.e. alkane, diphenyl and aza-alkane bisguanidines and bis(2-aminoimidazolines)] which were chosen for their structural similarity to the trypanocidal agents synthalin (1,10-decanediguanidine) and 4,4'-diguanidinodiphenylmethane, and the polyamine *N*^l-(3-amino-propyl)-propane-1,3-diamine respectively, is reported. The original synthetic procedure for the preparation of 21 of these compounds is also reported.

Most compounds displayed low micromolar anti-trypanosomal activity with five of them presenting a nanomolar inhibitory action on the parasite: 1,9-nonanediguanidine (**1c**), 1,12-dodecanediguanidine (**1d**), 4,4'-bis[1,3-di(*tert*-butoxycarbonyl)-2-imidazolidinylimino]diphenylamine (**28a**), 4,4'-bis(4,5-dihydro-1*H*-2-imidazolylamino)diphenylamine (**28b**), 4,4'-diguanidinodiphenylamine (**32b**) and 1,4-bis[4-(4,5-dihydro-1*H*-2-imidazolylamino)phenyl]piperazine (**41b**). Those molecules, which showed an excellent *in vitro* activity as well as high selectivity for the parasite [e.g. **1c** (IC₅₀ = 49 nM; SI > 5294), **28b** (IC₅₀ = 69 nM; SI = 3072), **32b** (IC₅₀ = 22 nM; SI = 29.5), **41b** (IC₅₀ = 118 nM; SI = 881)], represent new anti-trypanosomal lead compounds.

Keywords: polyamine, guanidine, 2-aminoimidazoline, *Trypanosoma brucei*, antiprotozoal, chemotherapy

Introduction

Sleeping sickness (Human African Trypanosomiasis, HAT) is caused by two subspecies of African trypanosomes, *Trypanosoma brucei gambiense* and *T. brucei rhodesiense*, responsible for the chronic and acute form of the disease respectively.¹ Only four drugs are licensed for the treatment of HAT² (DFMO, suramin, pentamidine and melarsoprol) although other drugs such as berenil (usually used against animal trypanosomiasis) or the nitrofurantoin nifurtimox (registered for use against Chagas' disease) have also proved useful in some limited cases. The actual situation of re-emergence of sleeping sickness in sub-Saharan Africa, with prevalence of an estimated 500,000 infected individuals,³ and the drawbacks of the current HAT chemotherapy (e.g. toxicity, increasing resistance, parenteral mode of administration, price) make the search for new trypanocidal drugs urgently needed.⁴

Many diamidine, diguanidine and polyamine compounds have been investigated for their antitrypanosomal activity as far as 65 years ago,⁵⁻¹¹ giving rise, for instance, to the aromatic diamidine drug pentamidine¹² which is still used nowadays for the treatment of early stage *T.b. gambiense* infections. However, this drug is unable to cross the blood-brain barrier in sufficient quantity to treat late-stage cases of HAT.¹³ Other aromatic diamidines such as propamidine or berenil are used as antiprotozoal chemotherapy in cattle and the trypanocidal activity of dicationic derivatives related to pentamidine have been reported as well (Figure 1).^{9,14,15} The polyamine metabolic pathway of trypanosomatid parasites has attracted much attention as drug target for the last 15 years.¹⁶ This research led to the synthesis and evaluation of many polyamine analogues as chemotherapeutic agents against parasitic infections,¹⁷⁻²⁰ being the trypanothione reductase a particularly targeted enzyme (Figure 1).²¹⁻²³

There is a clear lack of research investment in the field of tropical diseases in comparison to the number of affected population.^{24,25} Thus, a reasonable approach for the discovery of new anti-trypanosomal lead compounds at a lesser cost is the screening for anti-parasitic activity of already available molecules. Hence, a rapid look at the structure of the polyamine, diguanidine and diamidine compounds reported as antiprotozoal agents in the literature put into evidence the potential as possible trypanocides of a series of bisguanidine and bis(2-aminoimidazoline) compounds previously synthesized in our laboratory for other purposes.²⁶⁻²⁸ Moreover, some of the alkanediguanidine [1,8-octanediguanidine (**1b**),²⁹ 1,12-dodecanediguanidine (**1d**),^{6,30,31} bis(guanidinopropyl)amine (**6a**)³²] and diphenyl compounds [4,4'-diguanidinodiphenylmethane (**31b**), 4,4'-diguanidinodiphenylsulfone (**33b**)]⁸ available in our in-house library had been previously reported for their use as either trypanocide, microbicides or fungicides. Of particular interest was the recent report on *N,N'*-bis(4-amidinophenyl)piperazine (Figure 1) which proved to be a very effective anti-trypanosomal agent *in vivo*.¹⁵ Hence, in the search for new HAT chemotherapy, we decided to carry out an *in vitro* screening against the parasite *T. brucei rhodesiense* of a total of 62 compounds (Tables 1-5) taken from our in-house library and structurally related to the trypanocidal agents synthalin (1,10-decanediguanidine) and 4,4'-diguanidinodiphenylmethane (**31b**), and the polyamine *N'*-(3-amino-propyl)-propane-1,3-diamine respectively. We also describe here the original synthesis of 21 molecules which had not been previously reported.

Figure 1

Results

Chemistry

Synthesis of the aliphatic compounds **1a-d**, **2a-d**, **3b-d**, **4a-b**, **5a**, **5b**, **5d**, **6a-b**, **7**, **8**, **9**, **11-13**, **21-24** (Tables 1, 2, 3 and 4) as well as the diphenyl derivatives **27a-33a**, **27b-33b** and **34** (Table 5, entry 1-15) has been previously reported by us.^{26,27,28}

Synthesis of the 3-aza-1,6-hexanediamine derivatives (Scheme 1). Guanylation of 3-aza-1,6-hexanediamine with an excess of DCC in CH_3CN afforded a mixture of the di-substituted dicyclohexylguanidine derivative **5c** and the tri-substituted compound **17**. These products were separated by preparative reverse phase HPLC.

3-Aza-1,6-hexane diamine selectively protected on the primary amino group with benzylcyanoformate^{28,33} (**5d**) was used as starting material for the preparation of the 3-substituted derivatives **8-10**, **14-16**, **18-20** and **25-26** (Scheme 1). Alkylation of **5d** with bromoethylbenzene or 2-bromoethanol yielded **8** (83 %) and **20** (69 %) respectively. Hydrogenolysis of **8** with 10% Pd-C/1M HCl/MeOH afforded the amine **9** which was subsequently refluxed with S-methylisothiuronium sulphate in CH₃CN, yielding the bis-guanidine **10** (46 %). When **5d** was treated with chloroacetaldehyde in excess under reductive conditions (NaBH(OAc)₃/AcOH/CH₃CN) at room temperature, the chloroethyl derivative **19** (35 %) was obtained together with the acetate side-product **18** (16 %). In this reaction, the nucleophilic substitution of chloroacetaldehyde (or 2-chloroethanol derived from the reduction *in situ* of chloroacetaldehyde) by the secondary amine **5d**, leading to a hydroxyethyl intermediate that can react with AcOH present in the reaction medium, is a potential competitive reaction. Working at low temperature (0 °C) was unfavourable to the competitive nucleophilic substitution and **19** could be obtained in 69 % in these conditions.

An interesting feature was the methylation of **5d** with formaldehyde under reductive conditions (NaBH₃CN/CH₃CN).³⁴ Three main products were isolated depending on the pH of the reaction. Working in basic medium (i.e. pH > 7, no AcOH added) yielded the methylated product **14** (51 %) whereas acidic medium afforded both five and six-member ring amins **25** and **26** respectively. Structural characterisation of both derivatives was carried out by 1D (¹H, ¹³C) and 2D-NMR experiments (i.e. HSQC, HMBC). A characteristic difference between the ¹H NMR spectra of **25** and **26** were the amination methylene protons which appeared as a singlet of two protons for the six-member ring derivative **26** whereas two singlets (separated by 14.8 Hz) were observed for the five member ring counterpart **25**. This might account for the observation of two

conformers of the acyl derivative **25**.³⁵ Study of the $^3J_{\text{H-C}}$ coupling constants between the aminal methylene protons and their neighbours allowed to characterising both compounds.

Scheme 1. Reagents and conditions. (a) PhCH₂CO₂CN (2 equiv.), CH₂Cl₂; (b) HCHO, NaBH₃CN, AcOH (pH<7), MeCN; (c) HCHO, NaBH₃CN, MeCN (pH>7); (d) H₂, Pd-C 10%, MeOH, HCl 1M; (e) 2-methylmercapto-4,5-dihydroimidazole iodide, MeOH, reflux; (f) DCC, MeCN, rt; (g) 2-bromoethanol, MeCN, reflux; (h) chloroacetaldehyde (4 equiv.), NaBH(OAc)₃, AcOH, MeCN, rt; (i) bromoethylbenzene, K₂CO₃, CH₃CN, reflux; (j) S-methylisothiuronium sulfate, CH₃CN, reflux.

Synthesis of the diphenyl derivatives (Scheme 2). Guanidines **31c** and **32c** were obtained by reaction of an ether solution of *N*-(2,2'-diethoxyethyl)carbodiimide (prepared from BrCN and aminoacetaldehyde-diethylacetal)³⁶ with 4,4'-diaminodiphenylamine and 4,4'-diaminodiphenylmethane in the presence of CH₃SO₃H, respectively. Preparation of the 2-aminoimidazole **35** was carried out by base-catalysed cyclisation of the guanidine precursor **31c** following the methodology of Munk *et al.*³⁶ In this reaction, two cyclisation products could potentially form: (1*H*-imidazol-2-yl)-aryl-amine (“endocyclic” amino group) and 1-aryl-1*H*-imidazol-2-ylamine (“exocyclic” amino group). ¹H NMR spectrum of **35** showed a unique broad singlet for 4-H and 5-H imidazol protons at 6.76 ppm whereas decoupled ¹³C NMR spectrum showed a unique

signal for both 4- and 5- imidazole carbons indicating the magnetic equivalence of these atoms. These data demonstrated that the expected product **35** with the endocyclic amino group was obtained (e.g. if the isomer with exocyclic amino group were obtained, a typical AB system would be observed for the 4- and 5-H imidazol protons).

Scheme 2. Reagents and conditions. (a) N-(2,2'-diethoxyethyl)carbodiimide (2.2 equiv.); $\text{CH}_3\text{SO}_3\text{H}$ (2 equiv.); EtOH, reflux, 23h; (b) 1) 6M HCl, rt, 3h, 2) 10% NaOH, rt, 1h; (c) NBS, *t*-BuOOH, CCl_4 , reflux; (d) tri-*n*-pentylphosphine (4 equiv.); PhMe, reflux, 24h.

Compound **37** has been previously described³⁷ as a B_2 bradykinin receptor antagonist. The reported procedure was quite lengthy so we designed a three steps synthesis starting from 4,4'-dimethylbenzophenone. Radicalar bromination of 4,4'-dimethylbenzophenone with NBS/*t*-BuOOH/ CCl_4 allowed the formation of the dibromo-derivative compound **36** which was isolated by crystallisation from the reaction mixture (22 % yield). The low yield obtained could be explained by the formation of a mixture of mono- and poly-halogenated derivatives (e.g. three spots were observed by TLC of the crude reaction mixture).³⁸ The bis-phosphonium compound **37** was obtained by nucleophilic substitution of the bromine atoms of **36** with an excess of tri-*n*-pentylphosphine in refluxing toluene. Tri-*n*-pentylphosphine was prepared by a

modification of the procedure described by Davies *et al.*³⁹ The reaction of an excess of bromopentane Grignard's reagent with phosphorous trichloride working at -78 °C⁴⁰ afforded the tri-*n*-pentylphosphine which was purified by fractional distillation.

Synthetic approach for the preparation of the piperazine-based bisguanidine and bis(2-aminoimidazoline) compounds is depicted in scheme 3. Aromatic nucleophilic substitution of 1-fluoro-4-nitrobenzene with the commercially available 1-(4-nitrophenyl)-piperazine in DMSO at 100 °C afforded **38**.⁴¹ Nitro groups were reduced by catalytic hydrogenation (10 % Pd-C/HCl/MeOH) affording the amine **39**⁴². Introduction of the Boc-protected guanidine and imidazoline moieties (compounds **40a** and **41a** respectively) was carried out in good yield with *N,N'*-di(*tert*-butoxycarbonyl)thiourea⁴³ and *N,N'*-di(*tert*-butoxycarbonyl)imidazoline-2-thione²⁶ respectively. Removal of the Boc-protecting groups was accomplished by treatment with TFA, affording **40b** and **41b** as their trifluoroacetate salts.

Scheme 3. Reagents and conditions. (a) DMSO, 100 °C, 60h (73%); (b) H₂ (40 Psi), 10% Pd-C, HCl, MeOH, rt (59%); (c) *N,N'*-bis(*tert*-butoxycarbonyl)thiourea (2.2 equiv.), HgCl₂, Et₃N, DMF, 0 °C then rt (73%); (d) TFA, CH₂Cl₂ (88%); (e) *N,N'*-bis(*tert*-butoxycarbonyl)imidazoline-2-thione (2.2 equiv.), HgCl₂, Et₃N, DMF, 0 °C then rt (66%).

Biological results. *In vitro* anti-trypanosomal activity

The results of the determination of anti-trypanosomal activity against bloodstream form trypomastigotes of *T.b. rhodesiense* (strain STIB 900) are reported in Tables 1 to 5. All compounds displayed dose-dependant activities against *T.b. rhodesiense*, with IC_{50} ranging from 0.022 μ M to 113 μ M, and were selective for the parasite. Eight aliphatic (**1b-d**, **2b-d**, **13** and **17**) and 12 diphenyl derivatives (**27b**, **28a-b**, **31b-c**, **32a-c**, **34**, **37**, **40b** and **41b**) showed an $IC_{50} < 1 \mu$ M. Among the latter, five compounds had an IC_{50} in the nanomolar range (**1c**, **1d**, **28a**, **28b** and **32b**) with a selectivity index (SI) ranging from 13 (**1d**) to more than 5000 (**1c**).

Alkane and aza-alkane derivatives (Tables 1 and 2). The most potent compound within the alkane (Table 1) and aza-alkane (Table 2) derivative series was 1,9-nonanediguandine (**1c**) with $IC_{50} = 49$ nM and a remarkable selectivity for the parasite (SI > 5294). In these series, the guanidinium cation gave in general more active compounds (about 2 to 4-fold) than the 2-aminoimidazolinium counterpart (compare **1a-d** / **2a-d**). This was also true for the aza-alkane series (Table 2, **5a/5b** and **6a/6b**). Increasing the chain length of the methylene spacer ($n = 6, 8, 9, 12$) between either guanidinium or 2-aminoimidazolinium cations tended to increase the activity with the following order: $n = 6 < n = 8$ (ca 30-fold) $< n = 9 \sim n = 12$ (Table 1). Regarding the selectivity, the nine-methylene spacer (**1c** and **2c**) gave the best SI (5294 and 71) in both series. Noteworthy was the greater activity displayed by the dicationic derivatives **1b-d** and **2b-d** with respect to their monocationic counterparts (Table 1). This behaviour was also observed for the aza-alkane compound **6b** which was 3.5-fold more active than **7** (Table 2).

Tables 1 around here⁴⁴

Introduction of an unsubstituted nitrogen atom in the methylene chain (e.g. in the aza-alkane series, Table 2) tended to reduce the activity compared to alkyl spacer. This is exemplified by the activity of compounds **1a** and **2a** (8 and 19.3 μ M respectively) and their aza-analogues **5a** and **5b** (21.4 and 69.1 μ M respectively). Another interesting result was that of the dicyclohexylguanidine **5c** (IC_{50} = 2.4 μ M) which was 9-fold more active than the guanidine analogue **5a** (21.4 μ M). This result might reflect better pharmacokinetic properties of the more lipophilic derivative **5c** (i.e. to cross biological membranes).

Tables 2 around here

The dicyclohexylguanidine compound **17** (IC_{50} = 0.98 μ M) displayed the best activity and selectivity ($SI > 82$) of all the 3-aza-1,6-hexanediamine derivatives (Table 3). Again, it appeared that lipophilicity was an important factor for good activity. In this series, substitution of the secondary amino group with a phenethyl, 3(2-ethyl)indole or methyl group afforded molecules slightly more active than the parent compound (compare the activities of **10/5a**, **11/5b** and **16/5b**).⁴⁵ In addition, the amines protected with a carbobenzyloxy group (Cbz) were more active than their free amino counterparts (compare **8/9**, **12/13** and **14/15**). Regarding the effect of the substituent on the secondary nitrogen in the Cbz-protected series, the following results, in order of decreasing activity, were obtained: indole (**13**: 1 μ M) > methyl (**14**: 3.1 μ M) ~ phenethyl (**8**: 3.88 μ M) > CH_2CH_2OAc (**18**: 7.1 μ M) > CH_2CH_2OH (**20**: 14 μ M).

Table 3 around here

Worth mentioning is the result obtained for the cyclic analogues **25** and **26** (Table 4), which showed the same range of activity as the parent compound **14** ($IC_{50} = 3.1 \mu M$, Table 3) but a lower selectivity ($SI = 27$ and 18.6 respectively, compared to 41 for **14**). This behaviour was also observed with the cyclic analogue **23** ($71.2 \mu M$) which displayed the same activity as the aliphatic parent **5b** ($69.1 \mu M$).

Table 4 around here

Diphenyl derivatives (Table 5). In this series of bisguanidine and bis(2-aminoimidazoline) diphenyl analogues (Entry 1-17), best activities were observed for the compounds bearing a guanidinium group (from 3- to 10-fold with respect to the imidazoline analogues). However, the 2-aminoimidazoline derivatives displayed, in general, better selectivity than the guanidine counterparts (compare the activity and selectivity of **31b/27b**, **32b/28b**, **34/29b** and **32a/28a**). In addition, replacement of the guanidine or 2-aminoimidazoline with a 2-aminoimidazole nucleus (compound **35**, entry 18) produced a loss of activity of 20- and 63-fold compared to **28b** and **32b** respectively. Interestingly, the very lipophilic bis-phosphonium benzophenone derivative **37** showed a trypanocidal activity ($IC_{50} = 0.414 \mu M$) similar to that of the bisguanidinium diphenylketone **34** ($0.206 mM$) and a better selectivity ($SI = 28.5$ versus 13.1).

Notable is the effect of the N-substitution of the imidazoline and guanidine moieties (i.e. Boc, $CH_2CH(OEt)_2$). Boc protection afforded less active compounds compared to unprotected counterparts (compare **27a/27b**, **29a/29b**, **31a/31b**, **32a/32b**, **33a/ 33b** and

40a/40b) with the exception of **28** and **30** in which the Boc substituents produced a 1.4 and 12-fold increase in activity respectively ($IC_{50} = 0.048$ and $2.6 \mu M$ respectively) compared to the free imidazolinium cation ($IC_{50} = 0.069$ and $32.4 \mu M$ respectively). Moreover, the Boc substituents seemed to give somewhat less selective compounds (SI = 202 and 3072 for **28a** and **28b** respectively; SI = 7.9 and 29.5 for **32a** and **32b**). On the contrary, the 1,1-diethoxyethane substituent produced a great increase in selectivity, superior to 26- and 32-fold for **31c** and **32c** respectively, with only a slight loss in activity (2- and 10-fold respectively) compared to the unsubstituted parent compounds **31b** and **32b**.

Table 5 around here

Regarding the bridge linking both phenyl rings, the same behaviour was observed for the guanidinium and 2-aminoimidazolinium series, i.e. $NH \gg CH_2 > CO > SO_2$ in order of decreasing activity (compare **27b-30b** and **31b-33b**, **34**). When a piperazine moiety was used as bridge between both phenyl rings (Table 5, entry 21-25), the 2-aminoimidazolinium compound **41b** showed the best activity ($0.118 \mu M$) and also a 5 times higher selectivity (SI = 881) with respect to the guanidinium analogue (SI = 172).

Discussion

Some of the compounds described in this manuscript were available in our in-house library. Since few of these molecules had been previously reported in the literature for their anti-trypanosomal activity (e.g. **1d**,⁵ **31b**,⁸ **33b**¹⁰), we anticipated that our compounds would display trypanocidal action. Indeed, simple aliphatic diguanidines

were potent and selective trypanocides, with **3c** (SI > 5294) being more selective than the control melarsoprol (SI = 3456). The potency of **3c** is to be compared with that of synthalin (1,10-decanediguanidine)⁷ or 1,11-undecanediamidine, a trypanocidal drug which proved able to cure mice and rabbits infected with a strain of *T.b. rhodesiense*.⁶ The 1,9-nonanediguanidine **3c** could be considered as the bio-isostere of 1,11-undecanediamidine with the supplementary amino groups of the guanidine moieties playing the role of the two supplementary methylene units, thus keeping approximately the same chain length in both molecules.

In those series, the guanidine moiety afforded in general better trypanocidal drugs than the 2-aminoimidazoline one. Moreover, the presence of two cations was required for potent activity, which is in agreement with the results previously obtained by King *et al.*⁶ This assumption could probably be extended to the diphenyl series, according to the previous findings reported for aromatic diamidines and diguanidines,^{6,9,10} although this hypothesis was not tested here because mono-cationic aromatic compounds were not available in our library.

For short methylene chains (n = 5, 6, 7), introduction of a secondary nitrogen atom into the alkyl spacer afforded less active molecules although further substitution of this nitrogen could increase slightly the activity (compounds **8-20**). Conformational restriction of the aza-alkane molecules did not affect nor increase the trypanocidal action compared to their linear analogues (compounds **23**, **25** and **26**). The importance of lipophilicity of these molecules, facilitating drug uptake by the parasite by passive diffusion, was exemplified by the higher anti-trypanosomal activity of **5c** with respect to **5a**.

The most interesting results probably came from the diphenyl series with a NH bridge. The bis(2-aminoimidazoline) derivative **28b** was extremely potent (IC₅₀ = 69

nM) and also highly selective for the parasite (SI = 3072). The Boc-protected counterpart **28a** had the same range of activity but a lower selectivity index (SI = 202). This result in particular might be relevant because of the higher lipophilicity of the Boc-protected compound **28a**. Late-stage cases of HAT involve CNS infection and hence, require drugs able to cross the blood-brain barrier. However, the Boc-protecting group is probably stable in the conditions of the in vitro assay but potentially could be metabolised in vivo to afford the unprotected derivative **28b**.

Changing the 2-aminoimidazolinium cations for guanidinium ones led to the most active compound of this screening: **32b** (22 nM, SI = 29.5). The nature of the bridge linking both phenyl rings had a clear influence on the trypanocidal action of these compounds. Electron-donating groups such as NH, piperazine or CH₂ afforded better trypanocides than electron-withdrawing groups such as C=O or SO₂. Such behaviour was consistent with the findings of Donkor *et al.* in the pentamidine congener series where electron-rich phenyl groups (e.g. phenoxy) afforded better trypanocides than electron-poor phenyl rings (e.g. acetylated aniline or pyridine).¹⁵

If we compare the different cationic species studied (i.e. guanidinium, 2-aminoimidazolinium, phosphonium), the good activity and selectivity displayed by the bis-phosphonium derivative **37** (IC₅₀ = 0.414 μ M, SI = 28.5) is of particular interest. These results suggest that lipophilic bis-phosphonium diphenyl derivatives might be a good alternative (with potentially better pharmacokinetic properties) to the guanidine or 2-aminoimidazoline derivatives. With respect to the guanidine cation, N-substitution with a diethoxyethane moiety afforded highly selective anti-trypanosomal agents (SI > 754 and 767 for **31c** and **32c** respectively).

Anti-trypanocidal efficacy of a drug depends on its effective uptake by the parasite. It is known that diamidines such as pentamidine, which have very slow rate of diffusion

across biological membranes, can be transported into the cell by a P2-amino-purine transporter that specifically recognises the main $\text{H}_2\text{N}-\text{C}(\text{R}_1)=\text{NR}_2$ motif.^{46,47} The guanidine molecules reported here also present this recognition motif. In the case of the diphenyl derivatives, most of the Boc-protected molecules (i.e. the most lipophilic) showed a weaker activity than the charged, unprotected, guanidinium analogues. This might account for a more efficient transport of the unprotected derivatives through the P2 transporter, although affinity assays for this transporter remain to be done.

It is still too early to propose a mode of action of the compounds presented here and further studies are needed. However, a number of dicationic molecules belonging to the diamidine family (e.g. pentamidine) are known to bind to the minor-groove of DNA and their antiprotozoal activity is thought to be the result of that interaction (e.g. inhibition of DNA dependant enzymes or inhibition of transcription).⁴⁸⁻⁵⁰ In a recent article, Donkor *et al.* studied the trypanocidal activity of a series of conformationally restricted congeners of pentamidine.¹⁵ Although a direct correlation between the DNA binding affinity and the trypanocidal activity was not observed, the authors concluded that compounds with strong DNA affinity generally showed good trypanocidal activity in that series. In particular, *N,N'*-bis(4-amidinophenyl)piperazine (Figure 1) and *N,N'*-bis(4-imidazolinophenyl)piperazine were the most potent trypanocides and also the strongest DNA binders in this series. According to the results of Donkor *et al.*, we might expect good DNA binding affinity for compounds **40b** and **41b**, which are the guanidine and 2-aminoimidazoline analogues of these congeners respectively (*vide infra*). However, this hypothesis will need experimental confirmation.

Several compounds presented in this paper were first and foremost studied for different activities on the CNS (i.e. α_1 -adrenergic antagonism, I_2 -imidazoline binding site affinity or analgesic properties). The knowledge of these interactions (i.e. possible

side effects) is of importance because useful anti-trypanocidal agents are expected to penetrate the CNS to cure late-stage cases of HAT. The diphenyl compounds (Table 5, entries 5-8 and 12-15) present α_1 -adrenergic antagonist activity in various tissues.^{26,51} In particular, the blood pressure and heart rate responses of two compounds (**29b** and **31b**) had been tested on rats *in vivo*, suggesting a smaller magnitude of cardiovascular effects than the α_1 -adrenergic antagonist Doxazosin at the same dose.⁵² On the other hand, the alkane derivatives (Table 1, **1a-d** and **2a-d**) showed a moderate to good affinity for the I₂-imidazoline binding sites and α_2 -adrenoceptors in human brain membranes.²⁷ Finally, several aza-alkane derivatives (Tables 2 and 3: **4a-b**, **5a-b**, **6a-b**, **7**, **10**, **11**, **23**) were tested for analgesic activity in mice.²⁸ These data are relevant and should be taken into consideration when choosing possible lead compounds for *in vivo* assays.

Conclusion

We have reported here the screening for trypanocidal activity against *T.b. rhodesiense* of an in-house library of 62 compounds [i.e. alkane, diphenyl and aza-alkane bisguanidine and bis(2-aminoimidazoline)] which were chosen for their structural similarity to the trypanocidal agents synthalin (1,10-decanediguanidine), and 4,4'-diguanidinodiphenylmethane, and the polyamine *N*¹-(3-amino-propyl)-propane-1,3-diamine respectively. The original synthetic procedure for the preparation of 21 of these compounds was also reported.

The results of the determination of *in vitro* anti-trypanosomal activity allowed drawing some conclusions about the SAR of these series of molecules. Most compounds displayed low micromolar anti-trypanosomal activity with five of them presenting a nanomolar inhibitory action on the parasite (**1c**, **1d**, **28a**, **28b** and **32b**). Few of these compounds, which showed an excellent *in vitro* activity as well as high

selectivity, e.g. **1c** ($IC_{50} = 49$ nM; SI > 5294), **28b** ($IC_{50} = 69$ nM; SI = 3072), **32b** ($IC_{50} = 22$ nM; SI = 29.5), **41b** ($IC_{50} = 118$ nM; SI = 881) are promising lead compounds for anti-trypanosomal chemotherapy. The results of *in vivo* activity of these molecules will be reported in due course.

Tropical diseases mainly affect third-world countries which usually lack research capacities and financial resources for investigation. The lack of available funds and research in this field put into light the importance of screening in-house libraries of molecules already available in order to save time and money in the discovery of new lead compounds for neglected diseases like HAT.

Experimental Section

Chemistry. All reaction solvents were purchased anhydrous and used as received. Other solvents used were reagent grade. Reactions were monitored by TLC using pre-coated silica gel 60 F254 plates. Chromatography was performed either with silica gel 60 PF₂₅₄ (particle size 40-63 μ m) or with a medium pressure chromatography system using KP-Sil™ 40S or 40M cartridges (particle size 32-63 μ m, 60Å). All reactions requiring anhydrous conditions or an inert atmosphere were performed under a positive pressure of N₂. ¹H NMR and ¹³C NMR spectra were recorded at 200 and 50 MHz respectively, unless otherwise noted. Chemical shifts of the ¹H NMR spectra were internally referenced to the residual proton resonance of the deuterated solvents: CDCl₃ (7.26 ppm), D₂O (δ 4.6 ppm), CD₃OD (3.49 ppm) and DMSO (δ 2.49 ppm). Chemical shifts of ¹³C NMR and ³¹P spectra were referenced with a capilar of DMSO-d₆ (δ 39.5 ppm) and H₃PO₄ (δ 0 ppm) respectively. IR spectra were recorded as KBr pellets or neat. Melting points were determined with a Reichert-Jung Thermovar apparatus and

are uncorrected. Mass spectra were recorded on a Hewlett Packard Series 1100 MSD spectrometer (ES, APCI) and on a VG Autospec spectrometer (FAB). Elemental analysis was performed on a Heraeus CHN-O Rapid analyser. Analytical results were within ± 0.4 % of the theoretical values unless otherwise noted. Analytical HPLC was run on a Beckman LC-168 HPLC with either a Waters Delta Pak 5 μ -C18-100Å (3.9x150 mm) (column I) or a Varian Microsorb-MV-C18-100Å column (column II) using the following conditions: gradient time = 40 min and 15 min for columns I and II respectively, H₂O/CH₃CN (100:0→0:100) (TFA 0.1 %), flow rate = 1 mL/min, λ = 214 and 254 nm. Preparative HPLC (compounds **5c** and **17**) was carried out using a Waters Deltaprep apparatus with a Waters prepak®-RCM Base column and detection at 214 nm.

Compounds **1a**, **1b-1d**, **2a**, **2b**, **2c**, **2d**, **3b**, **3c**, **3d**, **4a-6a**,⁵³ **4b**, **5b**, **5d**, **6b**, **7**, **8**, **9**, **11**, **12**, **13**, **21**, **22**, **23**, **24**, **27a-33a**, **27b-33b** and **34** were prepared as previously reported.^{26-28, 53}

N-{3-[(2-Guanidino-ethyl)-phenethyl-amino]-propyl}-guanidine (10). A solution of **9** (0.5mmol) and S-methylisothiuronium sulfate (148 mg, 0.53 mmol) in dry MeOH (7 mL) was heated for 12 h at reflux. The solvent was removed by reduce pressure and the crude product dissolved in a mixture of H₂O/EtOH was treated with a few drops of 5 % H₂SO₄. The solution was allowed to stand 3 days in the fridge and the supernatant was discarded. Acetone was added and the oily residue was triturated with a spatula until the product crystallised. The solid was dried *in vacuo* affording **10** as a highly hygroscopic colorless solid (104 mg, 46 %). ¹H NMR (D₂O) δ 7.3-7.0 (m, 5H);

3.6-2.8 (m, 12H); 1.87 (m, 2H); ^{13}C NMR (D_2O) δ 155.9 (br); 135.0; 128.1; 127.7; 126.4; 53.0; 50.6; 49.9; 37.1; 35.4; 28.2; 22.7. LRMS (ES^+) m/e : 307 [(M+H)]; 100 %].

{3-[(2-Benzyloxycarbonylamino-ethyl)-methyl-amino]-propyl}-carbamic acid benzyl ester (14**)**. NaBH_3CN (100 mg, 1.49 mmol) was added to a solution of amine **5d** (443 mg, 1.15 mmol) and 37 % aqueous formaldehyde (0.4 mL, 4.6 mmol). The reaction was stirred 4 h at room temperature and the solvents were removed by reduce pressure. The crude residue was partitioned between CHCl_3 and water. The organic phase was collected and the aqueous phase was extracted 3 times with CHCl_3 . Organic extracts were washed with brine, dried (Na_2SO_4) and concentrated by reduce pressure. Flash chromatography (40S cartridge) with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (95:5) afforded the methylated amine **14** as a colorless solid (236 mg, 51 %); mp 60-62 $^\circ\text{C}$; IR (KBr) ν 3300, 2900, 2725, 1665, 1515, 1250, 1120, 960, 720, 685, 670 cm^{-1} ; ^1H NMR (CDCl_3) δ 7.4-7.2 (m, 10H); 5.6 (br, NH); 5.4 (br, NH); 5.07 (s, 2H); 5.05 (s, 2H); 3.3-3.1 (m, 4H); 2.5-2.3 (m, 4H); 2.17 (s, 3H); 1.62 (quint, 2H, $J = 6$ Hz); ^{13}C NMR (CDCl_3) δ 157.1; 137.3; 137.2; 129.0; 128.6; 128.5; 67.1; 67.0; 57.3; 55.9; 42.2; 40.1; 38.9; 27.4; LRMS (ES^+) m/e : 400 [(M+H), 100 %]; Anal. ($\text{C}_{22}\text{H}_{29}\text{N}_3\text{O}_4$) C, H, N.

N^I -(2-Amino-ethyl)- N^I -methyl-propane-1,3-diamine (15**)**. Catalytic hydrogenation of a suspension of **14** (230 mg, 0.57mmol), 10 % Pd-C (23 mg) and 1M HCl (1 mL) in MeOH (30 mL) under a 36 Psi hydrogen pressure for 24 h at room temperature afforded the HCl salt of **15** as a colorless oil (118 mg, quantitative). ^1H NMR (D_2O) δ 3.0-2.8 (m, 4H); 2.58 (t, 2H, $J = 6.8$ Hz); 2.46 (t, 2H, $J = 7.6$ Hz); 2.16 (s, 3H); 1.74 (quint, 2H, $J = 7.6$ Hz); ^{13}C NMR (D_2O) δ 54.8 (t); 54.5 (t); 41.0 (q); 38.5 (t); 37.0 (t); 24.5 (t); LRMS (APCI $^+$) m/e 132 [(M+H), 100 %]. Anal. ($\text{C}_6\text{H}_{20}\text{N}_3\text{Cl}_3$ / 0.3 H_2O) calcd: C, 29.47; H, 8.49; N, 17.19; found: C, 29.35; H, 8.40; N, 17.00.

***N,N'*-di[2-(4,5-dihydro-1*H*-imidazol-2-ylamino)-ethyl]-*N'*-methyl-propane-1,3-diamine (16).** A solution of **15** (110 mg, 0.84 mmol), 2-methylmercapto-4,5-dihydro-1*H*-imidazole iodide (410 mg, 1.76 mmol) in EtOH (10 mL) was heated 24 h at reflux (**CAUTION**: the noxious gas CH₃SH is evolved during the reaction and it should be trapped with a concentrated aqueous NaOH solution). The solvent was removed by reduce pressure and the crude compound was purified by formation of its picrate salt: a hot solution of picric acid (400 mg in 5 mL H₂O) was added to the hot reaction mixture and the flask was allowed to stand in the fridge for one week. The crystals were collected by filtration and rinsed successively with water, hexane and Et₂O. Picrate of **16**: yellow solid (302 mg, 53 %); mp 81-83 °C; ¹H NMR (400MHz, DMSO-*d*₆) δ 9.94 (br s, 1H); 9.25 (br s, 1H); 8.54 (s, 4H); 8.18 (t, 1H, *J* = 5.7 Hz); 8.13 (t, 1H, *J* = 4.8 Hz); 7.65 (br, 1H); 3.80 (s, 3H); 3.58 (s, 4H); 3.55 (s, 4H); 3.1 (m, 4H); 2.8-2.7 (m, 4H); 1.8 (br, 2H); ¹³C NMR (50 MHz, DMSO-*d*₆) δ 170.5; 160.9 (s); 159.4 (s); 141.5 (s); 125.3 (d); 124.8 (s); 53.6 (br, t); 53.0 (t); 45.2 (t); 42.6 (t); 40.2 (q); 37.2 (t); LRMS (FAB⁺) *m/e* 268 [(M+H)]. Anal. (C₂₄H₃₁N₁₃O₁₄) C, H, N.

3-Azahexane-1,7-(*N,N'*-dicyclohexyl)diguanidine (5c). A solution of 3-(2-aminoethylamino)propylamine (1 mL, 8.5 mmol) and DCC (3.7 g, 17.9 mmol) in dry CH₃CN (25 mL) was stirred 4 days at room temperature under argon atmosphere. The solvent was removed by reduce pressure and the crude oil was dissolved in Et₂O. A current of HCl_g was bubbled into the solution for 2 min. The white precipitate was collected, rinsed with Et₂O and dried *in vacuo* affording a mixture of the di- and tri-substituted compounds **5c** and **17** which were separated by preparative HPLC using the following eluent system: H₂O/CH₃CN (100:0→0:100) (TFA 0.1 %). Trifluoroacetate of **5c**: white solid; mp 88-93 °C; ¹H NMR (400 MHz, CDCl₃) δ 3.45 (t, 2H, *J* = 6.3 Hz); 3.6-3.25 (m, 10H); 3.18 (t, 2H, *J* = 7 Hz); 2.95 (br t, 2H); 1.82 (q, 2H, *J* = 7.8 Hz); 1.69

(br s, 8H); 1.60 (br d, 8H); 1.46 (br d, 4H); 1.16 (t, 16H, $J = 10$ Hz); 1.0 (br m, 5H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.7 (TFA); 154.0 (s); 154.0 (s); 117.6 (TFA); 52.6 (d); 52.5 (d); 47.3 (t); 46.5 (t); 39.3 (t); 38.9 (t); 33.4 (t); 33.4 (t); 26.5 (t); 25.8 (t); 25.7 (t); LRMS (ES^+) m/e 265,9 [(M+2H), 100 %]; 644.6 [(M+TFA)]; 758.6 [(M+2TFA)]; HPLC (column II): $R_t = 9.37$ min (100 %).

3-Azahexane-1,3,7-(*N,N'*-dicyclohexyl)triguanidine (17). Trifluoroacetate of **17**: white flocculent solid. ^1H NMR (500 MHz, CD_3OD) δ 3.73-3.60 (m, 8H); 3.56-3.44 (m, 6H); 2.14-1.8 (m, 30H); 1.7-1.3 (m, 32H); ^{13}C NMR (125 MHz, CD_3OD) δ 160.1 (s); 154.2 (s); 56.0 (d); 52.6 (d); 52.6 (d); 49.8 (t); 47.7 (t); 39.9 (t); 39.7 (t); 34.5 (t); 33.9 (t); 33.9 (t); 28.2 (t); 26.2 (t); 26.2 (t); 26.1 (t); 26.1 (t); 26.0 (t); LRMS (ES^+) m/e 369 [(M+2H), 100 %]; 246.5 [(M+3H)]; HPLC (column I): $R_t = 30.55$ min (99.58 %).

{3-[(2-Benzoyloxycarbonylamino-ethyl)-(2-chloro-ethyl)-amino]-propyl}-carbamic acid benzyl ester (19). Chloroacetaldehyde (50 % in water, 1.5 mL, 11.6 mmol) was added to a solution of **5d** (1.11 g, 2.9 mmol) in CH_3CN (20 mL). After a few minutes, AcOH (0.5 mL, 8.5 mmol) was added, followed 5 min later by $\text{NaBH}(\text{OAc})_3$ (1.24g, 5.8 mmol). The reaction mixture was stirred for 4 h at room temperature adjusting the pH to 5-6 with AcOH during the course of the reaction. The reaction was quenched by careful addition of 5 % NaHCO_3 and diluted with CH_2Cl_2 . The organic phase was separated and the aqueous phase was extracted 3 times with CH_2Cl_2 . Combined organic extracts were washed with brine, dried (Na_2SO_4) and concentrated by reduce pressure. Chromatography (40M cartridge) with petroleum ether/acetone (80:20) yielded the acetyl side-product **18** (16 %) and the expected chloro-derivative **19** as an oil that solidified as a yellowish pasty residue (450 mg, 35 %); IR (KBr): ν : 1680; 1415; 1240; 755; 713; 675 cm^{-1} ; ^1H NMR (CDCl_3) δ 7.29 (br s, 10H); 5.67 (br, NH); 5.60 (br, NH); 5.09 (s, 2H); 5.08 (s, 2H); 3.43 (t, 2H, $J = 6.1$ Hz); 3.3-3.1

(m, 4H); 2.68 (t, 2H, $J = 6.3$ Hz); 2.6-2.4 (m, 4H); 1.56 (quint, 2H, $J = 6.4$ Hz); ^{13}C NMR (CDCl_3) δ 157.0 (2C); 137.1; 128.8; 128.3; 66.8; 56.0; 54.0; 52.4; 42.5; 39.7; 39.3; 27.5; LRMS (ES^+) m/e 448.5 [(M+HCl), 100 %]; 412 [(M+H)]; Anal. ($\text{C}_{23}\text{H}_{30}\text{N}_3\text{O}_4\text{Cl} / \text{H}_2\text{O}$) calcd: C, 59.29; H, 6.92; N, 9.02; found: C, 59.27; H, 7.26; N, 9.02.

Acetic acid 2-[(2-benzyloxycarbonylamino-ethyl)-(3-benzyloxycarbonylamino-propyl)-amino]-ethyl ester (18). (223 mg, 16 %); ^1H NMR (CDCl_3) δ 7.28 (br s, 10H); 5.68 (br, NH); 5.52 (br, NH); 5.04 (s, 2H); 5.02 (s, 2H); 4.03 (t, 2H, $J = 5.6$ Hz); 3.25-3.05 (m, 4H); 2.60 (t, 2H, $J = 5.6$ Hz); 2.55-2.35 (m, 4H); 1.90 (s, 3H); 1.55 (quint, 2H); ^{13}C NMR (CDCl_3) δ 171.5; 157.0; 156.9; 137.1; 128.9; 128.5; 128.4; 66.95; 66.87; 62.4; 54.0; 52.7; 43.5; 39.9; 39.2; 27.3; 21.2; LRMS (ES^+) m/e 472 [(M+H), 100%]. Anal. ($\text{C}_{25}\text{H}_{33}\text{N}_3\text{O}_6$) C, H, N.

{3-[(2-Benzyloxycarbonylamino-ethyl)-(2-hydroxy-ethyl)-amino]-propyl}-carbamic acid benzyl ester (20). A solution of bromoethanol (0.03 mL, 0.42 mmol) in CH_3CN (1 mL) was added to a solution of **5d** (208 mg, 0.54 mmol) in CH_3CN (4 mL). The reaction mixture was refluxed 12 h and the solvent was removed by reduce pressure. The crude product was purified by chromatography with EtOAc/MeOH (80:20) and the resulting compound dissolved in a little CH_2Cl_2 was filtered on a path of *Celite* affording the pure product **20** (124 mg, 69 %). ^1H NMR (300 MHz, CDCl_3) δ 7.22 (br s, 10H); 5.63 (br, 1H); 5.46 (br, 1H); 4.97 (s, 4H); 3.44 (t, 2H, $J = 5$ Hz); 3.1 (m, 5H); 2.5-2.3 (m, 6H); 1.49 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 156.76; 156.57; 136.5; 128.3; 127.9; 66.4; 59.1; 55.8; 53.7; 51.3; 38.9; 38.6; 27.0; IR (neat) ν 3500-3300 (br); 2905; 1680; 1515; 1235; 715; 675 cm^{-1} ; LRMS (ES^+) m/z 430 [(M+H)], 542 [(M+Na), 100%]; Anal. ($\text{C}_{23}\text{H}_{31}\text{N}_3\text{O}_5 / 1 \text{ H}_2\text{O}$) calcd: C, 61.73; H, 7.43; N, 9.39; found: C, 61.83; H, 6.98; N, 8.82.

3-(3-Benzoyloxycarbonylamino-propyl)-imidazolidine-1-carboxylic acid

benzyl ester (25). To a solution of amine **5d** (1.06 g, 2.7 mmol) and formaldehyde (37 % in H₂O, 1.5 mL, 13.5 mmol) in CH₃CN was added NaBH₃CN (226 mg, 3.6 mmol). After 10 min, few drops of AcOH were added to the cloudy solution to adjust the pH to 6-7. The reaction was stirred 17 h at room temperature and the solvent was removed by reduce pressure. The crude residue was treated with water and 1M NaOH was added to adjust the pH to 10-11. The aqueous phase was extracted 3 times with CH₂Cl₂ and the organic extracts were dried (Na₂SO₄) and concentrated by reduce pressure. The crude oil was chromatographed (40M cartridge) with CH₂Cl₂/MeOH (98:2). The six-membered heterocycle **26** was eluted first followed by **25**. Compound **25**: ¹H NMR (300MHz, CDCl₃) δ 7.25 (m, 10H); 5.3 (br, 1H, NH); 5.04 (s, 2H); 4.99 (s, 2H); 3.94 (s, 1H); 3.89 (s, 1H); 3.37 (td, 2H, *J* = 8.9 and 9.3 Hz); 3.17 (td, 2H, *J* = 9.0 and 9.6 Hz); 2.70 (m, 2H); 2.43 (br t, 2H, *J* = 9 Hz); 1.58 (quint, 2H, *J* = 9.7 Hz); ¹³C NMR (300MHz, CDCl₃) δ 157.0; 154.4; 137.2; 129.0; 128.6; 68.8; 68.5; 67.4; 67.1; 53.4; 52.6; 52.2; 44.9; 44.7; 43.6; 40.2; 28.8; LRMS (ES⁺) *m/z* 398 [(M+H), 100 %].

3-(2-Benzoyloxycarbonylamino-ethyl)-tetrahydro-pyrimidine-1-carboxylic acid

benzyl ester (26). ¹H NMR (300 MHz, CDCl₃) δ 7.3 (br s, 10H, aro); 5.5 (br, 1H, NH); 5.1 [s, 2H, PhCH₂OC(O)NH]; 5.06 [s, 2H, PhCH₂OC(O)N]; 4.12 (s, 2H, NCH₂N); 3.48 (br t, 2H, *J* = 8.2 Hz, CbzNCH₂); 3.22 (br m, 2H, CH₂NHCbz); 2.67 (br t, 2H, NCH₂CH₂); 2.49 (m, 2H, NCH₂CH₂NHCbz); 1.53 (m, 2H, CH₂CH₂CH₂); ¹³C NMR (75 MHz, CDCl₃) δ 156.7 [s, C(=O)NH]; 155.28 [s, C(=O)N]; 136.94 (s, aro); 136.86 (s, aro); 128.7 (d, aro); 128.3 (d, aro); 128.1 (d, aro); 67.4 [t, PhCH₂OC(O)NH]; 66.7 [t, PhCH₂OC(O)N]; 65.1 (t, NCH₂N); 51.9 (t, NCH₂CH₂); 44.1 (t, CbzNCH₂); 38.3 (t, CH₂NHCbz); 22.5 (t, CH₂CH₂CH₂); LRMS (ES⁺) *m/z* 398 [(M+H), 100 %].

4,4'-Bis[*N*³-(2,2-diethoxyethyl)guanidino]diphenylmethane (31c). A 1M ether

solution of 2,2-diethoxy-ethyl-carbodiimide (11.1 mL, 11.1 mmol) was added to a solution of 4,4'-diaminodiphenylmethane (1.05 g, 5.3 mmol) in dry EtOH under N₂. Methanesulfonic acid (0.69 mL, 10.6 mmol) was added drop wise to the clear reaction mixture and a white precipitate formed immediately. The reaction was refluxed 44 h and then poured into 0.5 M aqueous NaOH solution. The aqueous phase was extracted (3×CH₂Cl₂). Organic extracts were dried (Na₂SO₄) and concentrated by reduce pressure. The guanidine **31c** was crystallised with CH₂Cl₂ and washed with Et₂O. Some more compound was obtained by precipitation of the mother liquor with Et₂O. Colorless solid (926 mg, 34 %); mp 188-190 °C; ¹H NMR (CDCl₃/CD₃OD) δ 7.0 (d, 4H, *J* = 7.5 Hz); 6.73 (d, 4H, *J* = 7.5 Hz); 4.44 (t, 2H, *J* = 4.8 Hz); 3.75 (s, 2H); 3.8-3.4 (m, 8H); 3.19 (d, 4H, *J* = 4.8 Hz); 1.12 (t, 12 H, *J* = 7 Hz); ¹³C (CDCl₃/CD₃OD) δ 154.5; 146.6; 136.1; 130.2; 124.2; 102.6; 63.8; 45.1; 41.2; 15.6; LRMS (EI) *m/z* 514 [(M⁺), 70 %], 485 [(M-29), 100 %]; Anal. (C₂₇H₄₂N₆O₄) C, H, N.

4,4'-Bis[*N*³-(2,2-diethoxyethyl)guanidino]diphenylamine (32c). Same procedure as **31c** starting from 4,4'-diaminodiphenylamine (421 mg, 2.1 mmol), 2,2-diethoxy-ethyl-carbodiimide (4.6 mL, 4.6 mmol) and methanesulfonic acid (0.27 mL, 4.2 mmol). The crude product dissolved in EtOH was treated with Et₂O. The solid precipitate was filtered off and the mother liquor was concentrated by reduce pressure. The residue was dissolved in MeOH and **32c** was isolated by Et₂O mediated precipitation (707 mg, 65 %); Methanesulfonate salt of **32c**: purple solid; IR (KBr) *ν* 1625; 1600; 1480; 1175; 1160; 1025; 1015; 750; 737 cm⁻¹; ¹H NMR (D₂O) δ 7.11 (s, 8H); 4.65 (m, 2H); 3.8-3.4 (m, 8H); 3.33 (m, 4H); 1.11 (t, 12H, *J* = 7.1 Hz); ¹³C NMR (D₂O) δ 156.7; 143.1; 127.8; 126.9; 118.9; 101.3; 65.0; 44.9; 15.2; LRMS (ES⁺) *m/e* 516 [(M+H), 100 %]. Anal. (C₂₈H₄₉N₇O₁₀S₂ / 2 H₂O) calcd: C, 45.21; H, 7.18; N, 13.18; S, 8.62; found: C, 44.80; H, 7.02; N, 12.70; S, 9.08.

4,4'-Bis(2-imidazolylamino)diphenylamine (35). In a flask cooled to 0 °C, was dissolved the guanidine **32c** (350mg, 0.68 mmol) in 6 M HCl (5 mL). After stirring 3 h at room temperature, 10 % NaOH was added until a precipitate formed (pH > 11). The reaction mixture was stirred 75 min and was poured into a 1M NaOH solution. The aqueous phase was extracted with CH₂Cl₂. The crude product was collected by filtration of the aqueous phase. The crude solid was dissolved in boiling water (10 mL) and the flask was allowed to stand overnight at room temperature. The product was collected by filtration, washed several times with H₂O and dried *in vacuo* at 50 °C affording the free base of **35** as a purple solid (82 mg). The hydrochloride salt was prepared in the following manner: to **35** dissolved in H₂O was added 3 N HCl until pH 2 was reached. The compound was lyophilised, dissolved in MeOH and purified by Et₂O mediated precipitation. Purple solid (51 mg, 19 %); mp > 200 °C (dec.); IR (KBr) ν 1650; 1590; 1500; 1310; 815; 670 cm⁻¹; ¹H NMR (D₂O) δ 7.15 (br s, 8H); 6.76 (br s, 4H); ¹³C NMR (D₂O) δ 145.9 (s); 142.5 (s); 130.2 (s); 125.4 (d); 119.8 (d); 114.0 (d); LRMS (ES⁺) *m/e* 332 [(M+H), 100 %]; 166.6 [(M+2H)]; Anal. (C₁₈H₂₀Cl₃N₇) calcd: C, 49.05; H, 4.57; N, 22.25; found: C, 49.71; H, 4.45; N, 21.66.

Bis-(4-bromomethyl-phenyl)-methanone (36). A solution of 4,4'-dimethylbenzophenone (1 g, 4.8 mmol), NBS (1.71 g, 9.6 mmol) and four drops of *t*-BuOOH in CCl₄ (15 mL) was heated at reflux for 18 h under argon atmosphere. The insoluble succinimide was filterered off and the solvent was removed by reduce pressure. The pure product was obtained by crystallisation from CH₂Cl₂ as colorless needles (387 mg, 22 %); mp 135-137 °C; IR (KBr) ν 1630, 1585, 1390, 1255, 1155, 905, 665 cm⁻¹; ¹H NMR (CDCl₃) δ 7.78 (d, 4H, *J* = 8.4 Hz); 7.51 (d, 4H, *J* = 8.4 Hz); 4.57 (s, 4H); ¹³C NMR (CDCl₃) δ 195.8; 142.9, 137.8, 131.1, 129.6, 32.9; Anal. (C₁₅H₁₂Br₂O / 0.5 H₂O) calcd: C, 47.78; H, 3.47; found: C, 47.87; H, 3.08.

Tri-*n*-pentylphosphine. To a suspension of magnesium (1.96 g) in dry THF (50 mL) under argon, was added a solution of 1-bromopentane (10 mL, 80.7 mmol) in THF (20 mL). The resulting reaction mixture was heated at reflux for 20 min. Then, the reaction was cooled to -78 °C and a solution of phosphorous trichloride (1.74 mL, 20 mmol) in THF (10 mL) was added drop wise. The reaction was stirred 30 min at -78 °C and the cold bath was removed. The reaction was allowed to warm up to room temperature and was then heated at reflux for 30 min. The reaction was quenched with saturated NH₄Br solution (20 mL). The precipitate was filtered off under argon atmosphere and the crude product was distilled under vacuum, affording the tri-*n*-pentylphosphine as a colorless oil (1.305 g, 27 %). The product was conserved under argon in the fridge. Bp (3 mm Hg) 115-125 °C; ¹H NMR (CDCl₃) δ 1.61 (m, 6H); 1.36 (m, 18H); 0.88 (m, 9H); ¹³C NMR (D₂O) δ 33.9 (d, *J*³¹P-¹³C = 13.7 Hz), 29.1, 27.8, 22.8, 22.0, 14.5; ³¹P NMR (CDCl₃) δ 50.23.

4,4'-Bis(tri-*n*-pentylphosphonium)benzophenone bromide (37). A solution of **36** (344 mg, 0.93 mmol) and tri-*n*-pentylphosphine (1.02 g, 4.2 mmol) in dry toluene (10 mL) was heated at reflux for 24 h. The precipitate that had formed while cooling the reaction mixture was triturated with a spatula until a solid formed. The solid was collected by filtration, rinsed with dry toluene and dried *in vacuo* at 70 °C. Colorless hygroscopic solid (748 mg, 94 %); Spectroscopic data are in agreement with the literature.³⁷ LRMS (FAB⁺) *m/e* 695.5 [(M⁺); 100%]; Anal. (C₄₅H₇₈OP₂Br₂) C, H.

1,4-Bis-(4-nitro-phenyl)-piperazine (38).⁵⁴ A solution of 1-(4-nitro-phenyl)-piperazine (2.58 g, 12.5 mmol) and 1-fluoro-4-nitrobenzene (599 mg, 4.16 mmol) in DMSO (15 mL) was heated 60 h at 100 °C. The cool reaction was poured into water (50 mL). The precipitate was collected by filtration and rinsed with a small quantity of water. The product was first crystallised with PhMe/EtOH and rinsed with cold toluene

and cold EtOH respectively. The pure compound was obtained as a red solid by crystallisation with CH₃CN (1g, 73 %). Mp 265-266 °C [Lit.⁵⁴ 261 °C, PhNO₂]; ¹H NMR (DMSO-d₆) δ 8.1 (d, 4H, *J* = 9 Hz); 7.0 (d, 4H, *J* = 9 Hz); 3.71 (s, 8H); ¹³C NMR (DMSO-d₆) δ 153.9; 136.8; 125.6; 111.9; 45.1. Anal. (C₁₆H₁₆N₄O₄ / 0.8 H₂O) calcd: C, 56.10; H, 5.18; N, 16.36; found: C, 56.12; H, 5.35; N, 16.24.

1,4-Bis-(4-amino-phenyl)-piperazine (39).⁴² The nitro compound **38** ((705 mg, 2.1 mmol) was dissolved in HCl saturated methanolic solution (70 mL). The solution was hydrogenated (40 Psi H₂) in the presence of 10 % Pd-C (165 mg) for 14 h at room temperature. The catalyst was filtered off and the solvent was removed by reduce pressure affording the crude hydrochloride of **39**. Recrystallisation with EtOH afforded the pure HCl salt of **39** (300 mg, 41%); mp > 350 °C; ¹H NMR (D₂O) δ 7.24 (s, 8H); 3.49 (s, 8H); LRMS (ES⁺) *m/z* 269 [(M+H), 100 %], 135 [(M+2H)]. Anal. (C₁₆H₂₄Cl₄N₄ / 1.7 H₂O) calcd: C, 43.40; H, 6.24; N, 12.65; found: C, 43.08; 5.49; N, 12.83.

1,4-Bis-[4-(N²,N³-di(*tert*-butoxycarbonyl)guanidino)-phenyl]-piperazine (40a). To a solution of **39** (54 mg, 0.2 mmol), *N,N'*-di(*tert*-butoxycarbonyl)thiourea (122 mg, 0.44 mmol), and Et₃N (0.14 mL, 1 mmol) in DMF (2 mL) at 0 °C under N₂ was added HgCl₂ (119 mg, 0.44 mmol) at once. A precipitate formed immediately. The resulting dark reaction mixture was stirred 30 min at 0 °C and 2.5 days at room temperature. The reaction was diluted with CH₂Cl₂ and filtered through a path of *Celite*. The filter cake was rinsed with CH₂Cl₂. the organic phase was washed with brine, dried (MgSO₄) and concentrated. Non-mobile impurities were removed by a short flash chromatography on silica with Hexane/EtOAc (75:25). The pure product was obtained by crystallisation from hexane. Yellowish solid (110 mg, 73 %); mp > 300 °C dec.; ¹H NMR (CDCl₃) δ 11.64 (br, 2H); 10.17 (br, 2H); 7.47 (d, 4H, *J* = 8.9 Hz); 6.92 (d, 4H, *J* = 8.9 Hz); 3.27 (s, 8H); 1.5 (br s, 36H); ¹³C NMR (CDCl₃) δ 164.2; 154.1; 153.9; 149.2;

130.0; 124.1; 117.4; 84.0; 79.9; 50.3; 28.7; LRMS (ES⁺) *m/z* 753 [(M+H)]; Anal. (C₃₈H₅₆N₈O₈ / 0.7 C₆H₁₄) calcd: C, 62.37; H, 8.16; N, 13.79; found: C, 62.23; H, 8.80; N, 14.11.

1,4-Bis-(4-guanidino-phenyl)-piperazine (40b). TFA (2 mL) was added to a stirred solution of **40a** (37 mg, 0.049 mmol) in CH₂Cl₂ (3 mL). After 2 days, the volatiles were removed by reduce pressure and the product was precipitated by addition of Et₂O. The compound was dried *in vacuo* affording **40b** as a greenish hygroscopic solid (25 mg, 88 %). Trifluoroacetic salt of **40b**. ¹H NMR (D₂O) δ 7.19 (m, 8H); 3.36 (s, 8H); ¹³C NMR (D₂O) δ 156.2; 148.4; 128.2; 127.1; 118.7; 49.4; LRMS (ES⁺) *m/z* 353 [(M+H)], 177 [(M+2H), 100%]. Anal. (C₂₄H₂₇F₉N₈O₆) calcd: C, 41.51; H, 3.92; N, 16.13; found: C, 41.52; H, 4.33; N, 17.04.

Di(*tert*-butyl) 2-(4-[4-(4-[1,3-di(*tert*-butoxycarbonyl)tetrahydro-1*H*-2-imidazolyliden]aminophenyl)piperazino]phenylimino)-1,3-imidazolidinedicarboxylate (41a). Same procedure as **40a** starting from the HCl salt of **39** (111 mg, 0.27 mmol), Et₃N (0.37 mL, 2.7 mmol), HgCl₂ (160 mg, 0.59 mmol) and using *N,N'*-di(*tert*-butoxycarbonyl)imidazoline-2-thione (178 mg, 0.59 mmol) as reagent for the introduction of the imidazoline nucleus. Flash chromatography with Hexane/EtOAc (50:50) afforded the product as a colorless solid (143 mg, 66 %). ¹H NMR (CDCl₃) δ 6.9 (m, 8H); 3.79 (s, 8H); 3.20 (s, 8H); 1.31 (s, 36H); ¹³C NMR (50MHz, CDCl₃) δ 150.3 (s); 147.2 (s); 141.5 (s); 138.5 (s); 122.1 (d); 117.3 (d); 82.4 (s); 50.4 (t); 42.9 (t); 27.7 (q); Anal. (C₄₂H₆₀N₈O₈) C, H, N.

1,4-bis[4-(4,5-dihydro-1*H*-2-imidazolylamino)phenyl]piperazine (41b). TFA (2 mL) was added to a stirred solution of **41a** (65 mg, 0.08 mmol) in CH₂Cl₂ (3 mL). After 12 h, the volatiles were removed by reduce pressure and the product dissolved in water was extracted with CH₂Cl₂ to remove organic soluble impurities. The water was

evaporated and the product was dried *in vacuo* to afford **41b** as a greenish hygroscopic solid. ¹H NMR (D₂O) δ 7.3-7.0 (br m, 8H); 3.63 (s, 8H); 3.59 (s, 8H); ¹³C NMR (CD₃OD, 75 MHz) δ 161.1; 152.5; 128.7; 127.4; 118.6; 50.6; 44.5; LRMS (ES⁺) *m/z* 405 [(M+H)]; 203.2 [(M+2H), 100 %]; Anal. (C₂₆H₃₀F₆N₈O₄) C, H, N.

Biological tests

***In Vitro* antitrypanosomal activity against *Trypanosoma brucei rhodesiense*.**

Minimum Essential Medium (50 µl) supplemented with 25 mM HEPES, 1g/l additional glucose, 1% MEM non-essential amino acids (100x), 0.2 mM 2-mercaptoethanol, 2mM Na-pyruvate, 0.1mM hypoxanthine and 15% heat inactivated horse serum was added to each well of a 96-well microtiter plate. 3-fold serial drug dilutions were prepared in duplicate in the columns covering a range from 90 µg/ml to 0.123 µg/ml. Then 10⁴ bloodstream forms of *T. b. rhodesiense* STIB 900 in 50 µl was added to each well and the plate incubated at 37 °C under a 5 % CO₂ atmosphere for 72 h. Alamar Blue (10 µl) was then added to each well and incubation continued for a further 2-4 h. Then the plates were read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an emission wave length of 588 nm. Data are analysed using the microplate reader software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA).

***In vitro* cytotoxicity with L-6 cells.** Assays were performed in 96-well microtiter plates, each well containing 100 µl of RPMI 1640 medium supplemented with 1% L-glutamine (200mM) and 10% fetal bovine serum, and 4 x 10⁴ L-6 cells (rat skeletal myoblasts) with or without a serial drug dilution columns covering a range from 90 µg/ml to 0.123 µg/ml. Each compound was tested in duplicate. After 72hours of

incubation the plates were inspected under an inverted microscope to assure growth of the controls and sterile conditions. 10µl of Alamar Blue was then added to each well and the plates incubated for another 2 hours. Then the plates were read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an emission wave length of 588 nm. Data were analysed using the microplate reader software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA).

Acknowledgment. We gratefully acknowledge the European Commission (Marie Curie Research Training grant, category 20), the Spanish MECD (SB2001-0174) and the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). The excellent technical assistance of Elke Gobright at the Swiss Tropical Institute is highly acknowledged.

References

- (1) <http://www.who.int/tdr/diseases/tryp/diseaseinfo.htm>
- (2) Pepin, J.; Milord, F.; Khonde, A.; Niyonsenga, T.; Loko, L.; Mpia, B. Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. *Trans R Soc Trop Med Hyg* **1994**, *88*, 447-452.
- (3) Barrett, M. P. The fall and rise of sleeping sickness. *Lancet* **1999**, *353*, 1113-1114.
- (4) Barrett, M. P. Problems for the chemotherapy of human African trypanosomiasis. *Curr Opin Infect Dis* **2000**, *13*, 647-651.
- (5) Jancso, N. Chemotherapeutic action and carbohydrate metabolism. The curative action of guanidine derivatives on trypanosome infections. *Z Immunitaetsforsch* **1935**, *86*, 1-30.
- (6) King, H.; Lourie, E. M.; Yorke, W. New trypanocidal substances. *Lancet* **1937**, *II*, 1360-1363.
- (7) Lourie, E. M.; Yorke, W. Studies in chemotherapy. XVI. The trypanocidal action of synthalin. *Ann Trop Med Parasitol* **1937**, *31*, 435-445.
- (8) King, H.; Lourie, E. M.; Yorke, W. Chemotherapy. XIX. Further report on new trypanocidal substances. *Ann Trop Med Parasitol* **1938**, *32*, 177-192.
- (9) Ashley, J. N.; Barber, H. J.; Ewins, A. J.; Newbery, G.; Self, A. D. H. A chemotherapeutic comparison of the trypanocidal action of some aromatic diamidines. *J Chem Soc* **1942**, 103-116.
- (10) Safir, S. R.; Kushner, S.; Brancone, L. M.; Subbarow, Y. Experimental chemotherapy of trypanosomiasis. II. The preparation of compounds related to p-phenylenediguanide. *J Org Chem* **1948**, *13*, 924-932.

- (11) Lourie, E. M.; Yorke, W. Studies in chemotherapy. XXI. The trypanocidal action of certain aromatic diamidines. *Ann Trop Med Parasitol* **1939**, *37*, 404.
- (12) Sands, M.; Kron, M. A.; Brown, R. B. Pentamidine: a review. *Rev Infect Dis* **1985**, *7*, 625-634.
- (13) Keiser, J.; Stich, A.; Burri, C. New drugs for the treatment of human African trypanosomiasis: research and development. *Trends Parasitol* **2001**, *17*, 42-49.
- (14) Donkor, I. O.; Assefa, H.; Rattendi, D.; Lane, S.; Vargas, M.; Goldberg, B.; Bacchi, C. Trypanocidal activity of dicationic compounds related to pentamidine. *Eur J Med Chem* **2001**, *36*, 531-538.
- (15) Donkor, I. O.; Huang, T. L.; Tao, B.; Rattendi, D.; Lane, S.; Vargas, M.; Goldberg, B.; Bacchi, C. Trypanocidal activity of conformationally restricted pentamidine congeners. *J Med Chem* **2003**, *46*, 1041-1048.
- (16) Muller, S.; Coombs, G. H.; Walter, R. D. Targeting polyamines of parasitic protozoa in chemotherapy. *Trends Parasitol* **2001**, *17*, 242-249.
- (17) Casero, R. A., Jr.; Woster, P. M. Terminally alkylated polyamine analogues as chemotherapeutic agents. *J Med Chem* **2001**, *44*, 1-26.
- (18) Edwards, M. L.; Prakash, N. J.; Stermerick, D. M.; Sunkara, S. P.; Bitonti, A. J.; Davis, G. F.; Dumont, J. A.; Bey, P. Polyamine analogues with antitumor activity. *J Med Chem* **1990**, *33*, 1369-1375.
- (19) Edwards, M. L.; Stermerick, D. M.; Bitonti, A. J.; Dumont, J. A.; McCann, P. P.; Bey, P.; Sjoerdsma, A. Antimalarial polyamine analogues. *J Med Chem* **1991**, *34*, 569-574.
- (20) Klenke, B.; Stewart, M.; Barrett, M. P.; Brun, R.; Gilbert, I. H. Synthesis and biological evaluation of s-triazine substituted polyamines as potential new anti-trypanosomal drugs. *J Med Chem* **2001**, *44*, 3440-3452.

- (21) Baillet, S.; Buisine, E.; Horvath, D.; Maes, L.; Bonnet, B.; Sergheraert, C. 2-Amino diphenylsulfides as inhibitors of trypanothione reductase: modification of the side chain. *Bioorg Med Chem* **1996**, *4*, 891-899.
- (22) Bonnet, B.; Soullez, D.; Davioud-Charvet, E.; Landry, V.; Horvath, D.; Sergheraert, C. New spermine and spermidine derivatives as potent inhibitors of *Trypanosoma cruzi* trypanothione reductase. *Bioorg Med Chem* **1997**, *5*, 1249-1256.
- (23) Bonnet, B.; Soullez, D.; Girault, S.; Maes, L.; Landry, V.; Davioud-Charvet, E.; Sergheraert, C. Trypanothione reductase inhibition/trypanocidal activity relationships in a 1,4-bis(3-aminopropyl)piperazine series. *Bioorg Med Chem* **2000**, *8*, 95-103.
- (24) Trouiller, P.; Olliaro, P. L. Drug development output: what proportion for tropical diseases? *Lancet* **1999**, *354*, 164.
- (25) Hirst, S. I.; Stapley, L. A. Parasitology: the dawn of a new millennium. *Parasitol Today* **2000**, *16*, 1-3.
- (26) Dardonville, C.; Goya, P.; Rozas, I.; Alsasua, A.; Martin, M. I.; Borrego, M. J. New aromatic iminoimidazolidine derivatives as α 1-adrenoceptor antagonists: a novel synthetic approach and pharmacological activity. *Bioorg Med Chem* **2000**, *8*, 1567-1577.
- (27) Dardonville, C.; Rozas, I.; Callado, L. F.; Meana, J. J. I(2)-imidazoline binding site affinity of a structurally different type of ligands. *Bioorg Med Chem* **2002**, *10*, 1525-1533.
- (28) Dardonville, C.; Rozas, I.; Goya, P.; Giron, R.; Goicoechea, C.; Martin, M. I. Synthesis and analgesic activity of a series of new azaalkane bis- guanidinium

- and bis(2-aminoimidazolinium) compounds. *Bioorg Med Chem* **2003**, *11*, 1283-1291.
- (29) Brown, J. G.; Payne, H. A. S. Fungicidal 1,8-diguanidinium salts; Patent GE 2219461, Offen: Germany, 1972.
- (30) Mueller, T.; Zipplies, M.; Ammermann, E.; Lorenz, G. Bisguanidines and fungicides containing them; Patent US005242948A, BASF Aktiengesellschaft: Germany, 1993.
- (31) Puetzer, B. Guanyl and biguanyl compounds; Patent US2213474; Winthrop Chemical Company: USA, 1940.
- (32) Ueda, T. Bis(guanidinopropyl)amine derivatives: Japan, 1963; pp 177.
- (33) Murahashi, S.-I.-.; Naota, T.; Nakajima, N. Chemoselective acylation of primary amines in the presence of secondary amines with acyl cyanide. *Chem Lett* **1987**, 879-882.
- (34) Borch, R. F.; Bernstein, M. D.; Durst, H. The cyanohydridoborate anion as a selective reducing agent. *J Am Chem Soc* **1971**, *93*, 2897-2904.
- (35) Katritzky, A. R.; Murugan, R.; Luce, H.; Chen, B. C.; Brey, W. S.; Zerner, M. C. Acyl derivatives of cyclic secondary amines. Part 2. Dynamic ^1H and ^{13}C nuclear magnetic resonance studies on bis- and tris-amides: equilibria of *syn-anti* interconversion. *J Chem Soc Perkin Trans II* **1987**, 1701-1705.
- (36) Munk, S. A.; Harcourt, D. A.; Arasasingham, P. N.; Burke, J. A.; Kharlamb, A. B.; Manlapaz, C. A.; Padillo, E. U.; Roberts, D.; Runde, E.; Williams, L.; Wheeler, L. A.; Garst, M. E. Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. *J Med Chem* **1997**, *40*, 18-23.

- (37) Douty, B. D.; Salvino, J. M.; Seoane, P. R.; Dolle, R. E. Synthesis of non-peptide bradykinin B2 receptor antagonists. *Bioorg Med Chem Lett* **1995**, *5*, 363-366.
- (38) Wenner, W. Bis(bromomethyl) compounds. *J Org Chem* **1952**, *17*, 523-527.
- (39) Davies, W. C.; Pearse, P. L.; Jones, W. J. Tertiary phosphines containing the higher alkyl radicals. *J Chem Soc* **1929**, 1264-1268.
- (40) Stone, G. A.; Kaesz, H. D. Preparation and characterization of vinylchlorophosphine, vinylmethylphosphine and ethyldimethylphosphine. *J Org Chem* **1959**, *24*, 635-637.
- (41) Aroney, M.; Le Fèvre, R. J. W. Molecular polarisability. The conformations of various N-substituted anilines, piperidines, and piperazines. *J Chem Soc* **1960**, 2161-2168.
- (42) Morley *Chem Ber* **1879**, *12*, 1796.
- (43) Poss, M. A.; Iwanowicz, E.; Reid, J. A.; Lin, J.; Gu, Z. A mild and efficient method for the preparation of guanidines. *Tetrahedron Lett* **1992**, *33*, 5933-5936.
- (44) Brun, R.; Buhler, Y.; Sandmeier, U.; Kaminsky, R.; Bacchi, C. J.; Rattendi, D.; Lane, S.; Croft, S. L.; Snowden, D.; Yardley, V.; Caravatti, G.; Frei, J.; Stanek, J.; Mett, H. In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. *Antimicrob Agents Chemother* **1996**, *40*, 1442-1447.
- (45) Note: the derivatised nitrogen atoms are presumably not protonated in the conditions of the assay.
- (46) Denise, H.; Barrett, M. P. Uptake and mode of action of drugs used against sleeping sickness. *Biochem Pharmacol* **2001**, *61*, 1-5.

- (47) De Koning, H. P. Uptake of pentamidine in *Trypanosoma brucei brucei* is mediated by three distinct transporters: implications for cross-resistance with arsenicals. *Mol Pharmacol* **2001**, *59*, 586-592.
- (48) Bailly, C.; Dassonneville, L.; Carrasco, C.; Lucas, D.; Kumar, A.; Boykin, D. W.; Wilson, W. D. Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives. *Anticancer Drug Des* **1999**, *14*, 47-60.
- (49) Tidwell, R. R.; Jones, S. K.; Geratz, J. D.; Ohemeng, K. A.; Cory, M.; Hall, J. E. Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental *Pneumocystis carinii* pneumonia. *J Med Chem* **1990**, *33*, 1252-1257.
- (50) Cory, M.; Tidwell, R. R.; Fairley, T. A. Structure and DNA binding activity of analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine). *J Med Chem* **1992**, *35*, 431-438.
- (51) Dannert, M.; Alsasua, A.; Borrego, M. J.; Dardonville, C.; Sánchez, M.; Martin, M. I. Effects of new alpha-adrenoceptor antagonists in human prostatic tissues from patients with benign prostatic hypertrophy. *Methods Find Exp Clin Pharmacol* **2002**, *24*, Suppl. A, 158.
- (52) Borrego, M. J.; Alsasua, A.; Dardonville, C.; Rozas, I.; Martin, M. I. Study of new alpha-adrenoceptor antagonists in rat blood pressure. *Methods Find Exp Clin Pharmacol* **2002**, *24*, Suppl. A, 99.
- (53) Villarroja, M.; Gandia, L.; Lopez, M. G.; Garcia, A. G.; Cueto, S.; Garcia-Navio, J. L.; Alvarez-Builla, J. Synthesis and pharmacology of alkanediguandinium compounds that block the neuronal nicotinic acetylcholine receptor. *Bioorg Med Chem* **1996**, *4*, 1177-1183.

- (54) Aroney, M.; Le Fèvre, R. J. W. Molecular polarisability. The conformations of various N-substituted anilines, piperidines and piperazines. *J Chem Soc* **1960**, 2161-2163.

Table 1. Structure, in vitro trypanocidal activity and cytotoxicity of guanidine and 2-aminoimidazoline alkane derivatives **1a-3d**.

<div style="border: 1px solid black; padding: 5px; display: inline-block;"> $R_1-(CH_2)_n-R_2$ </div>						
Compound	n	R ₁	R ₂	<i>T. brucei rhodesiense</i> IC ₅₀ (μM) ^a	Cytotoxicity L6-cells IC ₅₀ (μM)	Selectivity ^b
1a	6			8.05	>302	> 37
1b	8			0.251	>276	> 1100
1c	9			0.049	>265	> 5294
1d	12			0.047	0.63	13
2a	6			19.3	-	-
2b	8			0.453	4.2	9.4
2c	9			0.225	16	71
2d	12			0.107	2.35	22
3b	8	H		49.1	-	-
3c	9	H		19.9	-	-
3d	12	H		11.0	19.6	1.8

^a Controls: melarsoprol IC₅₀ = 5.5 nM (SI= 3456); diminazene diacetate IC₅₀ = 8.9 nM; CGP 40215 IC₅₀ = 4.5 nM [ref 43]. ^b Selectivity index (SI) expressed as the ratio [IC₅₀ L6-cells / IC₅₀ *T.b. rhodesiense*]

Table 2. Structure, in vitro trypanocidal activity and cytotoxicity of guanidine and 2-aminoimidazoline aza-alkane derivatives **4a-7**.

<div style="display: flex; align-items: center; justify-content: space-around;"> <div style="border: 1px solid black; padding: 5px; margin-right: 10px;"> $R-X-R$ </div> <div> $R = \text{Gua: } \begin{array}{c} \text{H} \\ \diagup \\ \text{N} \\ \diagdown \\ \text{NH}_2 \end{array}$ </div> <div> $R = \text{Imi: } \begin{array}{c} \text{H} \\ \diagup \\ \text{N} \\ \diagdown \\ \text{HN} \end{array}$ </div> <div> $R = \text{Gua-C}_6\text{H}_{11}: \begin{array}{c} \text{C}_6\text{H}_{11} \\ \diagup \\ \text{N} \\ \diagdown \\ \text{NH} \end{array}$ </div> </div>				
Compd	R	X	<i>T. brucei rhodesiense</i> IC ₅₀ (μM) ^a	Cytotoxicity L6-cells IC ₅₀ (μM)
4a	Gua		16.1	-
4b	Imi		84.4	-
5a	Gua		21.4	-
5b	Imi		69.1	-
5c	Gua-C ₆ H ₁₁		2.4	-
6a	Gua		21.2	-
6b	Imi		29.7	-
7	Imi		113.1	-

^a Controls: melarsoprol IC₅₀ = 5.5 nM (SI= 3456); diminazene diacetate IC₅₀= 8.9 nM; CGP 40215 IC₅₀ = 4.5 nM [ref 43]. ^b Selectivity index (SI) expressed as the ratio [IC₅₀ L6-cells / IC₅₀ *T.b. rhodesiense*]

Table 3. Structure, in vitro trypanocidal activity and cytotoxicity of 3-aza-1,6-hexanediamine derivatives **8-20**.

Compd	R	R'	<i>T. brucei rhodesiense</i> IC ₅₀ (μM) ^a	Cytotoxicity L6-cells IC ₅₀ (μM)	Selectivity ^b
8	Cbz		3.88	24.7	6.4
9	H		17.4	214	12
10	Gua		4.5	>199	> 43
11	Imi		27.6	-	-
12	H		13.8	-	-
13	Cbz		1.0	7.8	7.8
14	Cbz		3.1	130	41
15	H	CH ₃	61.8	-	-
16	Imi		46.6	-	-
17	Gua-C ₆ H ₁₁	Gua-C ₆ H ₁₁	0.98	>83	> 82
18	Cbz		7.1	>191	> 26
20	Cbz		14.0	116	8.3

^a Controls: melarsoprol IC₅₀ = 5.5 nM (SI= 3456); diminazene diacetate IC₅₀ = 8.9 nM; CGP 40215 IC₅₀ = 4.5 nM [ref 43]. ^b Selectivity index (SI) expressed as the ratio [IC₅₀ L6-cells / IC₅₀ *T.b. rhodesiense*]

Table 4. Structure, in vitro trypanocidal activity and cytotoxicity of 3-aza-1,6-hexanediamine cyclic derivatives **21-26**.

Compd	Structure	R	<i>T. brucei rhodesiense</i> IC ₅₀ (μM) ^a	Cytotoxicity L6- cells IC ₅₀ (μM)	Selectivity ^b
21		H	57.9	-	-
22		Boc	30.3	-	-
23		Imi	71.2	-	-
24			12.6	-	-
25		Cbz	3.9	106	27
26		Cbz	4.78	89	18.6

^a Controls: melarsoprol IC₅₀ = 5.5 nM (SI= 3456); diminazene diacetate IC₅₀ = 8.9 nM; CGP 40215 IC₅₀ = 4.5 nM [ref 43].

^b Selectivity index (SI) expressed as the ratio [IC₅₀ L6-cells / IC₅₀ *T.b. rhodesiense*]

Table 5. Structure, *in vitro* trypanocidal activity and cytotoxicity of diphenyl derivatives **27a-41b**.

Entry	Compd	R	X	<i>T. brucei</i> <i>rhodesiense</i> IC ₅₀ (μM) ^a	Cytotoxicity L6-cells IC ₅₀ (μM)	Selectivity ^b
1	27a		CH ₂	11.6	-	-
2	28a		NH	0.048	9.8	202
3	29a		CO	7.2	-	-
4	30a		SO ₂	2.6	56.4	21.7
5	27b		CH ₂	0.897	63.6	71
6	28b		NH	0.069	212	3072
7	29b		CO	2.05	>214	> 104
8	30b		SO ₂	32.4	-	-
9	31a		CH ₂	31.7	-	-
10	32a		NH	0.470	3.7	7.9
11	33a		SO ₂	24.4	-	-
12	31b		CH ₂	0.161	2.8	17.4
13	32b		NH	0.022	0.65	29.5
14	33b		SO ₂	4.3	>222	> 51
15	34		CO	0.206	2.7	13.1
16	31c		CH ₂	0.316	>175	> 554
17	32c		NH	0.228	>175	> 767
18	35		NH	1.4	113	80.7
19	36	Br	CO	25.9	>244	> 9.4
20	37	P ⁺ (<i>n</i> -C ₅ H ₁₁) ₃	CO	0.414	11.8	28.5
21	38	NO ₂		41.8	-	-
22	39	NH ₂		1.42	>217	> 152
23	40a			13.8	-	-
24	40b			0.270	46.4	172
25	41b			0.118	104	881

^a Controls: melarsoprol IC₅₀ = 5.5 nM (SI= 3456); diminazene diacetate IC₅₀ = 8.9 nM; CGP40215 IC₅₀ = 4.5 nM [ref 43]. ^b Selectivity index (SI) expressed as the ratio [IC₅₀ L6-cells / IC₅₀ *T.b. rhodesiense*]